Hemorrhagic regression of melanoma metastases during therapeutic vaccination: A report of three cases

Melanoma Research

Volumn 19, Issue 6, 2009, Pages 385-390

  Pierret, Lauranne ^a,b   Van Baren, Nicolas ^c   Bonehill, Aude ^d   Corthals, Jurgen ^d   Van Nuffel, An M T ^d   Heirman, Carlo ^d   Roelandt, Truus ^b   De Coninck, Arlette ^b   Van Riet, Ivan ^b   Degreef, Ellen ^b   Goossens, Annieta ^b   Verfaillie, Guy ^b   Roseeuw, Diane ^b   Thielemans, Kris ^a,d   Neyns, Bart ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Dendritic cell vaccine; Hemorrhagic; Melanoma; Metastasis; Peptide vaccine

Indexed keywords

ALPHA2B INTERFERON; CELECOXIB; CISPLATIN; CORTICOSTEROID DERIVATIVE; DACARBAZINE; DENDRITIC CELL VACCINE; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; MELANOMA VACCINE; PEPTIDE VACCINE; TEMOZOLOMIDE;

ADRENAL METASTASIS; ADULT; AMELANOTIC MELANOMA; ARTERY BLOOD FLOW; ARTICLE; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN SURGERY; BREAST METASTASIS; BREAST SURGERY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DISTANT METASTASIS; DOPPLER ECHOGRAPHY; DRUG TREATMENT FAILURE; ECCHYMOSIS; FEMALE; HEART METASTASIS; HEMATOMA; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; PRIORITY JOURNAL; REMISSION; SKIN METASTASIS; SUBCUTANEOUS HEMORRHAGE; SURGICAL DRAINAGE; TREATMENT DURATION;

ADULT; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; VACCINATION;

EID: 73349132354     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832eabb5     Document Type: Article

References (32)

1. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles & Practice of Oncology. Philadelphia: W.W. Lippincott; 2008.
2. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007; 34:555-565.
3. Zhang SW, Zhang DF, Sun BC. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007; 254:157-164.
4. Torok L, Kirschner A, Ocsai H, Olasz K. Hematoma-like metastasis in melanoma. J Am Acad Dermatol 2003; 49:912-913.
5. Dereure O, Blatiere V, Guillot B. Multiple haemorrhagic-like cutaneous metastasis of malignant melanoma. Eur J Dermatol 2005; 15:409-410.
6. Antunes AC CM, Coutinho LM. Hemorrhage in intracranial metastases of melanoma. Report of 2 cases. Arq Neuropsiquiatr 1979; 37:180-184.
7. DeHart WK, Gilliam AC, Lu KQ, Brell J. A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses. Arch Dermatol 2008; 144:561-562.
8. Jouary T, Delaunay M, Taieb A. Hematoma-like metastases. J Am Acad Dermatol 2006; 55:1106-1107.
9. Connolly CM, Soldin M, Dawson A, Cooper AC. Metastatic malignant melanoma presenting with a bruise. Br J Plast Surg 2003; 56:76. (Pubitemid 36603756)
10. Dawson-Bowling S, Greig A, Healy C, Connolly CM, Soldin M, Dawson M, Cooper ACSM. Metastatic malignant melanoma presenting with a bruise. Br J Plast Surg 2003; 56:76.
11. Br J Plast Surg 2004; 57:691-692.
12. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. Neurology 1982; 32:A73-A73.
13. Kondziolka D, Bernstein M, Resch L, Tator CH, Fleming JF, Vanderlinden RG, et al. Significance of hemorrhage into Brain-Tumors-Clinicopathological Study. J Neurosurg 1987; 7:852-857.
14. Little JR, Dial B, Bélanger G, Carpenter S. Brain hemorrhage from intracranial tumor. Stroke 1979; 10:283-288.
15. Halefoglu A, Ertürk M, Ozel A, Calişkan KC. Acute lymphoblastic leukemia presenting with multiple hemorrhagic brain metastases. Case report. Tani Girisim Radyol 2004; 10:119-120.
16. Mori H, Abe O, Aoki S, Masumoto T, Yoshikawa T, Kunimatsu A, et al. Hemorrhagic brain metastases with high signal intensity on diffusion-weighted MR images. Acta Radiol 2002; 43:563-566.
17. Isoda H, Takahashi M, Arai T, Ramsey RG, Yokoyama T, Mochizuki T, et al. Multiple haemorrhagic brain metastases from papillary thyroid cancer. Neuroradiology 1997; 39:198-202.
18. Baydar M, Dikilitas M, Sevinc A, Senel S, Senel F, Aydogdu I. Cutaneous metastasis of endometrial carcinoma with hemorrhagic nodules and papules. Eur J Gynaecol Oncol 2005; 26:464-465.
19. Kalialis LV, Drzewiecki KT, Mohammadi M, Mehlsen AB, Klyver H. Spontaneous regression of metastases from malignant melanoma: a case report. Melanoma Res 2008; 18:279-283.
20. Baldo M, Schiavon M, Cicogna PA, Boccato P, Mazzoleni F. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast Reconstr Surg 1992; 90:1073-1076.
21. McCarthy WH, Shaw HM, Milton GW. Spontaneous regression of metastatic malignant melanoma. Clin Oncol 1978; 4:203-207.
22. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915.
23. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T-cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208.
24. Finn OJ. Cancer Immunology. N Engl J Med 2008; 358:2704-2715.
25. Van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T-cells. J Clin Oncol 2005; 23:9008-9021.
26. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; 6:1175-1188.
27. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1513-1537.
28. Neyns B, Corthals J, Thielemans K. Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. ASCO Meeting Abstracts 2007; 25 (18 Suppl):8537.
29. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, et al. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39:70-77.
30. Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, et al. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother 2007; 56:753-759.
31. Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 2006; 55:178-784.
32. Carrasco J, Van Pel A, Neyns B, LethéB, Brasseur F, Renkvist N, et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 2008; 180:3585-3593.